The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery

被引：18

作者：

Davis, SS ^{[1
]}

机构：

[1] Univ Nottingham, Inst Pharmaceut Sci, Nottingham NG7 2RD, England

来源：

VACCINE | 2006年 / 24卷

关键词：

chitosan; microspheres; nasal;

D O I：

10.1016/j.vaccine.2005.01.102

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

It is important when developing new vaccine systems to give proper attention to the question of delivery. In some cases the judicious choice of a delivery system can provide a greatly enhanced immune response and avoid the need to use a vaccine adjuvant. Delivery systems that have been developed originally for the administration of challenging drug can be used with success for vaccines. Polymer microspheres and lamellar particle based on the biodegradable materials polylactide and polylactide co-glycolide can be employed for the improved parenteral and mucosal administration of antigens. Likewise soluble biopolymers such as chitosan can be used for the improved nasal delivery of various antigens as well as DNA. Results from animal studies and recent clinical trials are provided. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：S7 / S10

页数：4

共 12 条

[1]

Illum L, 1998, PHARM RES-DORDR, V15, P1326

[2] Chitosan as a novel nasal delivery system for vaccines [J].

Illum, L ;

Jabbal-Gill, I ;

Hinchcliffe, M ;

Fisher, AN ;

Davis, SS .

ADVANCED DRUG DELIVERY REVIEWS, 2001, 51 (1-3) :81-96

[3] Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice [J].

Iqbal, M ;

Lin, W ;

Jabbal-Gill, I ;

Davis, SS ;

Steward, MW ;

Illum, L .

VACCINE, 2003, 21 (13-14) :1478-1485

[4] Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines [J].

Jabbal-Gill, I ;

Lin, W ;

Jenkins, P ;

Watts, P ;

Jimenez, M ;

Illum, L ;

Davis, SS ;

Wood, JM ;

Major, D ;

Minor, PD ;

Li, XW ;

Lavelle, EC ;

Coombes, AGA .

VACCINE, 1999, 18 (3-4) :238-250

[5] Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a [J].

Mills, KHG ;

Cosgrove, C ;

McNeela, EA ;

Sexton, A ;

Giemza, R ;

Jabbal-Gill, I ;

Church, A ;

Lin, W ;

Illum, L ;

Podda, A ;

Rappuoli, R ;

Pizza, M ;

Griffin, GE ;

Lewis, DJM .

INFECTION AND IMMUNITY, 2003, 71 (02) :726-732

[6]

Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595

[7] CONTROLLED RELEASE MICROPARTICLES FOR VACCINE DEVELOPMENT [J].

OHAGAN, DT ;

JEFFERY, H ;

ROBERTS, MJJ ;

MCGEE, JP ;

DAVIS, SS .

VACCINE, 1991, 9 (10) :768-771

[8] One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate [J].

Okada, H .

ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (01) :43-70

[9] Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers [J].

Venkataprasad, N ;

Coombes, AGA ;

Singh, M ;

Rohde, M ;

Wilkinson, K ;

Hudecz, F ;

Davis, SS ;

Vordermeier, HM .

VACCINE, 1999, 17 (15-16) :1814-1819

[10]

Wilding I, 2000, Pharm Sci Technol Today, V3, P385, DOI 10.1016/S1461-5347(00)00311-4

← 1 2 →